Parathyroid Adenoma Detection With Rubidium-82 Imaging
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMatthieu Pelletier-Galarneau, MD MSc
About this trial
Assess the uptake of rubidium-82 in parathyroid adenomas.
Eligibility criteria
Qualifiers
Age ≥ 18y
Ability to undergo imaging logistics
Ability to provide informed consent
Biochemical evidence of primary hyperparathyroidism
Disqualifiers
Normocalcemic primary hyperparathyroidism
Breastfeeding or pregnancy
Claustrophobia or inability to undergo imaging logistics
Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study
Trial design
Treatments tested in this trial
- PET/CT imaging with rubidium-82
Treatment groups
No treatment groups listed
Sponsors and collaborators
Matthieu Pelletier-Galarneau, MD MSc
Lead sponsor
Montreal Heart Institute
Sponsor institution
Source ClinicalTrials.gov